NOV 0 2 2006 W

Docket No. PRD2124USPCT

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ſ

Applicants: Dominique Mabire

Serial No. : 10/595,882

Art Unit:

Filed

: November 18, 2004

Examiner:

For

: 7-PHENYLALKYL SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES AS POLY(ADP-RIBOSE)

POLYMERASE INHIBITORS

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

October 30, 2006
(Date of Deposit)

Alana G. Kriegsman
(Name of applicant, assignee, or Registered Representative)

/Alana G. Kriegsman/
(Signature)

October 30, 2006

(Date of Signature)

Mail Stop: Patent Application

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

IFW

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

X In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with [ ] the first or Second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or  $\Box$ Please charge Deposit Account No. 10the fee of \$180.00 as set forth / in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

	Statement in Accordance with §1.97(e)
	(attached); or
	Please charge Deposit Account No. 10-
	0750/ / the fee of \$180.00 as set forth
	in §1.17(p).
☐ In a	accordance with §1.97(d), this Information
Disclosure Sta	atement is being filed after the mailing date of
either a Final	Action under §1.113 or a Notice of Allowance
under §1.311	but before the payment of the Issue Fee.
Applicant(s) h	nereby petition(s) for consideration of this
Information Di	sclosure Statement. Included are: Statement in
Accordance wit	th §1.97(e) as set forth below and the fee of
\$180.00 as set	forth in §1.17(p).
	ies of each of the references listed on the
attached Form	PTO-1449 are enclosed herewith.
☐ Copi	ies of references listed on the attached Form PTO-
1449 are enclo	osed herewith EXCEPT THAT:
	In view of the voluminous nature of references
	[list as appropriate], and the likelihood that
	these references are available to the Examiner,
	copies are not enclosed herewith.
	If any of the foregoing publications are not
	available to the Examiner, Applicant will
	endeavor to supply copies at the Examiner's
	request.
⊠ Copi	ies of only foreign patent documents and non-
patent literat	ure are enclosed in accordance with 37 CFR 1.98
(a)(2).	

-----

-----

	references which are not in the
English language.	
$\square$ The relevance of the	ose listed references which are
not in the English language is	s as follows:
_	
<u>-</u>	of search report(s) from
corresponding patent applicati	ion(s), which are listed on the
attached Submission Under MPER	9 609 D.
_	
Attached are the following	llowing non-published pending
patent applications which may	be deemed relevant, which are
listed on the attached Submiss	sion Under MPEP 609 D.
Please charge any deficie	ency or credit any overpayment to
Deposit Account No. 10-0750/PF	RD2124USPCT/AGK. This form is
submitted in triplicate.	
	Respectfully submitted,
	/Alana G. Kriegsman/
	Alana G. Kriegsman
•	Reg. No. 41,747
	Attorney for Applicants
Johnson & Johnson	
One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003	
(732) 524-1495	

DATED: October 30, 2006

NOV 0 2 2006 W

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a conection of information unless it displays a valid OMB control number.					
Application Number	10/595,882				
Filing Date	11/18/2004				
First Named Inventor	Dominique Mabire				
Group Art Unit					
Examiner Name					
Attorney Docket Number	PRD2124USPCT				

U.S. PATENT DOCUMENTS							
		U.S. Patent Do	ocument		Data of Bublication	Pages, Columns, Lines,	
Examiner Initials	Cite No. <sup>1</sup>	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	where relevant passages relevant figures appear	
		5177075		Wamer-Lambert Company	01-05-1993		
						7	

#### **FOREIGN PATENT DOCUMENTS**

		Foreign Patent Document			Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No.1	Office <sup>3</sup> Number <sup>4</sup> KindCode <sup>5</sup>		KindCode <sup>5</sup>	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T <sup>6</sup>
		EP	0371564	B1	Janssen Pharmaceutica, N.v.	06-06-1990		
						-		

Examiner	Date	
Signature	Consider	ed

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a concention of information anicos it displays a	TOTAL CHIEF CONTROL PLANTS OF THE PROPERTY OF
Application Number	10/595,882
Filing Date	11/18/2004
First Named Inventor	Dominique Mabire
Group Art Unit	
Examiner Name	
Attorney Docket Number	PRD2124USPCT

	_	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
		ALI et al., "Synthesis and Antimicrobial Activities of Some Novel Quinoxalinone Derivatives", Molecules, 2000, pages 864-873, Vol. 5, No. 6, 'Online Computer File'.	
		KULCSAR et al., "Synthesis and Study of New 4-Quinazolinone Inhibitors of the DNA Repair Enzyme Poly (ADP-ribsose) Polymerase (PARP)", ARKIVOC, XX,XX, June 11, 2003, pages 121-123, Vol. 2003, No. PART V, XP002291367.	
		LI et al., "PARP Inhibitors", IDrugs, 2001, pages 804-812, Vol. 4, No. 7, Current Drugs Ltd., GB.	
		WELTIN et al., "Effect of 6(5-Phenanthridinone, an Inhibitor of Poly(ADP-ribose) Polymerase, on Cultured Tumor Cells", Oncology Research, 1994, pages 399-403, Vo.I. 6, No. 9, Elsevier Science Ltd., USA.	

Examiner	Date
	l l
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

NOV 0 2 2006 SUBMISSION UNDER MPEP 609 D

Application Number 10/595,882 Filing Date First Named Inventor 11/18/2004 Dominique Mabire Group Art Unit Examiner Name Attorney Docket Number PRD2124USPCT

Page 1 of 1

U.S. PATENT DOCUMENTS U.S. Patent Document Pages, Columns, Lines, where relevant passages or relevant figures appear Name of Patentee or Applicant Examiner Initials Cite Kind Code<sup>2</sup> of Cited Document Number (if known) No.1

FOREIGN PATENT DOCUMENTS

		FUREIG	N PATENT				
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Foreign P	Patent Docum	rent KindCode <sup>5</sup>	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
				_			
			-		_		
				<u> </u>			<u> </u>
		<del>v</del> -					
	! —— <u> </u>	OTHER PRIOR ART - I					L
Examiner 's Initials*	Cite No.1	Include name of the author (in 0 title of the item (book, magazin volume-issue number(	e, journal, s	erial, symp	osium, catalo	g, etc.), date, page(s),	T²
		PCT Intl. Search Report, PCT/EP2004	/013162, Ma	rch 18, 2005			
						•	

Examiner	Dat	e
Signature	Cor	sidered